How does one dissolve a brick in a beaker of water?
This is a question that James Pipkin, vice president of new product development at Ligand Pharmaceuticals and The University of Kansas answers in this interview.
Today’s cyclodextrin is a great story, case-study and learning opportunity about the rise of one of the most important players in the cyclodextrin industry.
Inspiring!
From Molecule to Market (lawrencebusinessmagazine.com)
Scientists create first mouse model with complete, functional human immunesystem and a human-like gutmicrobiome that is capable of mounting specific antibody responses.
Such a model would have unlimited uses in pharma development. The work of Paolo Casali et al groundbreaking and will disrupt the animal models we use for efficacy and safety studies. How would you use this model first? I imagine studies with vaccines probably…
Nature Immunology, 5 July 2024
Today’s cyclodextrin is C&EN‘s recent paper on PFAS removal out of drinking water features cyclodextrins too among other solutions.
The Chicago-based water purification company Cyclopure is looking beyond traditional activated carbon and ion-exchange resins. It uses β-cyclodextrins from plant-based products like corn and potato starch to remove PFAS from water.
For the past 4 years, the company has been optimizing conditions for polymerizing, purifying, and granulating β-cyclodextrins, which it purchases in bulk from WACKER. The plant-based sorbent, sold under the name Dexsorb, has a high capacity for PFAS, it takes up less space than GAC and can be regenerated.
Today, Cyclopure provides various industrial and consumer solutions with their technology
Public water utilities in the US are facing a 5-year deadline to meet low parts-per-trillion limits for six per- and polyfluoroalkyl substances (PFAS) in drinking water. The Environmental Protection Agency estimates that thousands of water systems will need to install advanced treatment processes to meet the limits. Utilities are eyeing several technologies to remove PFAS, including ion-exchange resins, granular activated carbon, and plant-based sorbents. But eventually they will need to replace such media, and what to do with the PFAS-laden spent media becomes the next challenge. Sustainability goals, concerns about liability related to PFAS in waste, and potential supply chain issues from soaring demand for PFAS removal media are pushing companies to develop methods for regenerating spent media and destroying the PFAS. But it’s unclear how water utilities will pay for technology to remove PFAS from their drinking water, as well as what the cost of replacing and disposing of media will be.
Getting PFAS out of drinking water (acs.org)
What a fascinating cyclodextrin application from L’Oréal. Formulations of a reducing agents and a cyclodextrins are proposed for removing color from keratin fibers such as hair.
This invention underlines the vast potential of CDs in cosmetic applications. If you would like to learn how you can develop a CD-based product yourself, this is the best place to look: Formulation development – www.carbohydesolutions.com
Link to patent: US20240197599 COMPOSITIONS AND METHODS FOR REMOVING COLOR FROM HAIR (wipo.int)
Today’s cyclodextrin is about the intrinsic anti-inflammatory properties of CDs.
Inflammation is an essential contributor to the pathophysiology of numerous diseases, and dysregulation of the involved signaling cascades often culminates in uncontrollable disease progression and, ultimately, chronification. Effectively addressing these disorders is challenging due to their inherent complexity and the need to mitigate inflammation while preserving essential immune functions.
Amphihilic cyclodextrin-based nanoparticles exhibit significant downregulation of crucial pro-inflammatory markers, along with changes in inflammasome activation and the lipid profile of pro-inflammatory macrophages after CD nanoparticle application. The findings of this study underscore the potential of cyclodextrin-based nanoparticles as versatile biomaterials for treating the complex pathophysiology of various acute and chronic inflammation-associated disorders.
Anti–inflammatory effects of cyclodextrin nanoparticles enable macrophage repolarization and combat inflammation | Research Square
Felix E. B. Brettner, Annika Haessler, Jonas Schreiner et al from Goethe University Frankfurt
Today’s cyclodextrin: After a long time, HPBCD will be evaluated again in clinics, now in a new application.
ZyVersa Therapeutics Inc. is sponsoring this Phase 2a open-label, two- to three-center study to evaluate the clinical efficacy and safety of one dose level of 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) given intravenously in adult patients with type 2 diabetes, diabetic kidney disease (DKD), and proteinuria.
According to the proposed mechanism of action, HPBCD entraps and passively removes intracellular cholesterol from the kidney. It is also believed to promote active cholesterol removal through up-regulation of cholesterol efflux transporters ABCA1 and ABCG1.
Today’s cyclodextrin is an excellent example of using CDs (in this particular case, HPBCD) in peptide/protein formulations. ELGAN Pharma‘s patent concerns combining insulin, cyclodextrins, and other components, where the role of the CD is stabilization and cryopreservation.
As we see more examples of CD-protein combinations in research and clinical practice, I am convinced that this use will shape future applications.
Using cyclodextrins to prevent aggregation in protein formulations has been known for some time, and we have already published a lot about this topic.
This paper from Florian Johann, Steffen Wöll, and Henning Gieseler adds some special spice to the application as they investigate the potential of CDs in reducing aggregation of Antibody–Drug Conjugates with different payloads.
The main takeaways of the study are:
Hydroxypropylated (CDs) reduced agitation-induced aggregation in all tested ADCs without causing destabilization during incubation at 40 °C.
Native CDs that are not surface active partially reduced agitation-induced aggregation in ADCs, suggesting the possibility of stabilizing mechanisms beyond mere competition at the air-liquid interface.
ADC-specific formulation effects were observed, e.g., superior performance of the large HPγCD type in stabilizing a highly unstable ADC with a bulky fluorophore payload during incubation.
Today’s cyclodextrin paper by CarboHyde CSO Milo Malanga PhD, in collaboration with former colleagues from Cyclolab R&D Ltd. and Budapest University of Technology and Economics, sheds light on the potential of cyclodextrins to inhibit bacterial communication through quorum sensing.
Quorum sensing is vital for bacteria to coordinate activities, but inhibiting this process can be a game-changer in combating bacterial infectivity. Cyclodextrins encapsulate signal molecules, disrupting bacterial communication and, consequently, the expression of virulence factors.
Excitingly, our research shows that cyclodextrins exhibit a notable inhibitory effect on the quorum-sensing system of A. fischeri. The impact varies with alkyl chain length, with alkylthio substitution amplifying inhibition and quaternary ammonium groups mitigating it. These findings highlight cyclodextrins’ potential as a promising therapeutic avenue for treating bacterial infections.
As a company also involved in research for Alzheimer’s disease both from the DDS and API perspective, we cheer for this news!
The U.S. Food and Drug Administration (FDA) has approved Kisunla™ (donanemab-azbt), a once-monthly injection (350 mg/20 mL) for IV infusion developed by Eli Lilly and Company.
Kisunla is designed to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) and mild dementia stages of AD, with confirmed amyloid pathology. This is the first and only amyloid plaque-targeting therapy that allows stopping treatment when amyloid plaques are cleared, potentially reducing costs and the number of infusions needed.
FDA approves new drug to treat Alzheimer’s disease (nbcnews.com)